Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 8.86 is 30% below its 5-year average of 12.70, near the low end of its 5-year range (7.10–39.39).
As of the fiscal period ended Tuesday, June 30, 2026. 9.20% below its 12-month average of 9.76.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.86.
QUICK RATIO (ACID-TEST)
8.86
QUICK RATIO (ACID-TEST) AVG TTM
9.76
QUICK RATIO (ACID-TEST) AVG 3Y
10.35
QUICK RATIO (ACID-TEST) AVG 5Y
12.70
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-9.20%
CURRENT VS 3Y AVG
-14.41%
CURRENT VS 5Y AVG
-30.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.28
median of 792 covered companies
CURRENT VS SECTOR MEDIAN
+170.22%
vs the sector median at left
Olema Pharmaceuticals, Inc.
Market Cap
$707.08M
Quick Ratio (Acid-Test)
8.86
TTM Avg
9.76
3Y Avg
10.35
5Y Avg
12.70
Market Cap
$702.89M
Quick Ratio (Acid-Test)
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
Market Cap
$714.52M
Quick Ratio (Acid-Test)
0.84
TTM Avg
1.18
3Y Avg
1.08
5Y Avg
1.08
Market Cap
$717.39M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.81
3Y Avg
5.95
5Y Avg
7.14
Market Cap
$718.19M
Quick Ratio (Acid-Test)
14.16
TTM Avg
12.98
3Y Avg
15.39
5Y Avg
17.04
Market Cap
$688.65M
Quick Ratio (Acid-Test)
14.20
TTM Avg
2.59
3Y Avg
2.42
5Y Avg
2.06
Market Cap
$730.93M
Quick Ratio (Acid-Test)
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$681.76M
Quick Ratio (Acid-Test)
13.82
TTM Avg
5.67
3Y Avg
7.51
5Y Avg
7.66
Market Cap
$737.10M
Quick Ratio (Acid-Test)
16.09
TTM Avg
8.04
3Y Avg
7.87
5Y Avg
9.13
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $707.08M | 8.86 | 9.76 | 10.35 | 12.70 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $702.89M | 19.31 | 14.05 | 7.67 | 5.91 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $714.52M | 0.84 | 1.18 | 1.08 | 1.08 |
| Cytek Biosciences, Inc. (CTKB)vs › | $717.39M | 3.86 | 4.81 | 5.95 | 7.14 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $718.19M | 14.16 | 12.98 | 15.39 | 17.04 |
| Anteris Technologies Global Corp. (AVR)vs › | $688.65M | 14.20 | 2.59 | 2.42 | 2.06 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $730.93M | 0.95 | 4.92 | 2.98 | 5.72 |
| Solid Biosciences Inc. (SLDB)vs › | $681.76M | 13.82 | 5.67 | 7.51 | 7.66 |
| Candel Therapeutics, Inc. (CADL)vs › | $737.10M | 16.09 | 8.04 | 7.87 | 9.13 |
| Faeth Therapeutics, Inc. (FTH)vs › | $739.61M | 19.69 | 6.38 | 9.16 | 11.87 |
Quick Ratio
8.86
Excludes inventory
Current Ratio
8.86
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 8.86 |
| 2026-03-31 | 10.88 |
| 2025-12-31 | 9.95 |
| 2025-09-30 | 8.03 |
| 2025-06-30 | 11.09 |
| 2025-03-31 | 15.22 |
| 2024-12-31 | 10.50 |
| 2024-09-30 | 7.10 |
| 2024-06-30 | 9.13 |
| 2024-03-31 | 9.61 |
| 2023-12-31 | 12.33 |
| 2023-09-30 | 17.66 |
| 2023-06-30 | 11.56 |
| 2023-03-31 | 9.76 |
| 2022-12-31 | 12.62 |
| 2022-09-30 | 17.93 |
| 2022-06-30 | 19.75 |
| 2022-03-31 | 26.57 |
| 2021-12-31 | 32.23 |
| 2021-09-30 | 34.63 |
| 2021-06-30 | 39.39 |
| 2021-03-31 | 62.59 |
| 2020-12-31 | 74.62 |
| 2020-09-30 | 24.48 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.07 |
